we deliver first-in-class solutions and technologies to provide a brighter future for those at risk of losing their sight. EyePoint specializes in the development of sustained-release drug delivery to treat debilitating diseases of the eye and other localized, chronic conditions.
Vorolanib Brings a Potential New MOA to the Treatment of VEGF-Mediated Retinal Diseases by Blocking all Isoforms of VEFG and PDGF
SoC=standard of care; ANG=angiopoietin; PDGF(R)=platelet-derived growth factor (receptor); PLGF=placental growth factor; TIE-2=tyrosine-protein kinase receptor; VEGF(R)=vascular endothelial growth factor (receptor).
Drug embedded within a bioerodible matrix covered with non-erodible polyimide shell:
Verisome® technology is a novel, sustained-delivery platform
DEXYCU is approved for the treatment of inflammation following ocular surgery.
EyePoint technologies have broad applicability across many therapeutic areas. Our validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. EyePoint seeks additional strategic partners to collaborate on the development of new sustained-release drug suspensions and inserts, to access complementary research, and to expand our product portfolio.